Delving into the Latest Updates on KRC-01 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Locally Advanced Cervical Carcinoma

Inactive Indication-

Originator Organization

KORTUC, Inc.Startup

Active Organization

KORTUC, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

This is a seamless Phase 1/2 study consisting of two components. Phase 1 component is a dose-escalation, single arm, open label study in 10 patients to evaluate the safety and tolerability of KRC 01. Phase 2 component is a randomized, open label, controlled, multi-center study in 60 patients to evaluate the preliminary antitumor effect of KRC-01 in combination with CRT.

Start Date01 Apr 2025

Sponsor / Collaborator

KORTUC, Inc.Startup

100 Clinical Results associated with KRC-01

Login to view more data

100 Translational Medicine associated with KRC-01

Login to view more data

100 Patents (Medical) associated with KRC-01

Login to view more data

1

Literatures (Medical) associated with KRC-01

01 Apr 1988·Hybridoma

Mouse Monoclonal Antibodies with Restricted Specificity for Human Renal Cell Carcinoma and Ability to Modulate the Tumor Cell Growth In Vitro

Article

Author: Tokuyama, H ; Tokuyama, Y

Three mouse monoclonal antibodies (MAbs), KRC-1, -2 and -3(IgG1) were produced against cultured cells of human renal cell carcinoma (RCC) cell lines. All of them had restricted specificity for subset of RCC, but did not react with other tumor cell lines, tumor and normal tissues including kidney. The effect of these MAbs on the tumor cell growth in vitro was examined both in soft agar and in plate culture systems. All of them showed modulator effect on the tumor cell growth: KRC-1 showed stimulation effect and others, KRC-2 and -3, suppression one in the both systems. The specificity was observed in the modulator effects. KRC-1 detected a 135 kd glycoprotein in immunoblotting. KRC-2 detected a high molecular weight antigen (ca. 1200 kd) in gel filtration. All the antigens showed affinity for Con A lectin. Molecular properties of the antigens appeared to be different from those of previously reported RCC-associated antigens. The three MAbs seem to be useful to study mechanism of growth regulation in transformed cells.

100 Deals associated with KRC-01

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Cervical Carcinoma	Phase 1	TH	KORTUC, Inc.Startup	01 Apr 2025
Locally Advanced Cervical Carcinoma	Phase 1	IN	KORTUC, Inc.Startup	01 Apr 2025
Locally Advanced Cervical Carcinoma	Phase 1	GB	KORTUC, Inc.Startup	01 Apr 2025